Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Terumo Cardiovascular Systems Corp.

Division of Terumo Corp.
www.terumo-cvs.com

Latest From Terumo Cardiovascular Systems Corp.

Top Asia Execs To Watch: WuXi NextCode, Fosun Kite, Novartis Japan

The coming of spring has brought a flurry of senior executive moves at companies across Asia including WuXi, Fosun-Kite, Novartis, BGI and Chi-Med.

Appointments Asia Pacific

LAA Closure Devices: Reaching Critical Mass?

Transcatheter LAA closure devices are starting to amass the level of data required to demonstrate their safety and effectiveness, and, if all goes well, the long-awaited FDA approval of the first such device – Boston Scientific’s Watchman – could finally occur sometme next year. Although LAA closure devices have already taken off in some European countries, US physicians continue to struggle with lingering uncertainties, about the learning curve, procedural safety and how LAA closure will stack up against newer anticoagulant drugs. Regardless of how these issues are eventually resolved, industry leaders see a big opportunity for a successful device in the LAA closure space, with market estimates of $1 billion considered conservative by some.

Medical Device

Deals Shaping The Medical Industry (03/2012)

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Prescient Medical's Dual Approach to Vulnerable Plaque

Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Terumo Corp.
  • Senior Management
  • Contact Info
  • Terumo Cardiovascular Systems Corp.
    Phone: (734) 663-4145
    6200 Jackson Rd.
    Ann Arbor, MI 48103-9300
    USA
UsernamePublicRestriction

Register